Article · Journal · 2026

Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis

Basile Njei, Yazan Al-Ajlouni, Dam Nsoh Tanih, Ulrick Sidney Kanmounye, Sarpong Boateng, Khaled W. Halwani and 2 more

Cost Effectiveness and Resource Allocation

• Open access · Gold
• World top 10%
• International · 3 countries

Read it10.1186/s12962-026-00741-0